MX339196B - Composiciones de aripiprazol y metodos para su suministro transdermico. - Google Patents

Composiciones de aripiprazol y metodos para su suministro transdermico.

Info

Publication number
MX339196B
MX339196B MX2013004693A MX2013004693A MX339196B MX 339196 B MX339196 B MX 339196B MX 2013004693 A MX2013004693 A MX 2013004693A MX 2013004693 A MX2013004693 A MX 2013004693A MX 339196 B MX339196 B MX 339196B
Authority
MX
Mexico
Prior art keywords
transdermal delivery
methods
aripiprazole compositions
aripiprazole
compositions
Prior art date
Application number
MX2013004693A
Other languages
English (en)
Other versions
MX2013004693A (es
Inventor
Fotios M Plakogiannis
Muhammed Anwar Hossain
Original Assignee
Aequus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aequus Pharmaceuticals Inc filed Critical Aequus Pharmaceuticals Inc
Publication of MX2013004693A publication Critical patent/MX2013004693A/es
Publication of MX339196B publication Critical patent/MX339196B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Secondary Cells (AREA)

Abstract

La presente invención divulga composiciones de formulación líquida y de gel que contienen aripiprazol en la forma de un parche para el suministro transdérmico.
MX2013004693A 2010-10-28 2011-10-20 Composiciones de aripiprazol y metodos para su suministro transdermico. MX339196B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40759110P 2010-10-28 2010-10-28
PCT/US2011/057080 WO2012058091A2 (en) 2010-10-28 2011-10-20 Aripiprazole compositions and methods for its transdermal delivery

Publications (2)

Publication Number Publication Date
MX2013004693A MX2013004693A (es) 2013-11-01
MX339196B true MX339196B (es) 2016-05-16

Family

ID=45994667

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004693A MX339196B (es) 2010-10-28 2011-10-20 Composiciones de aripiprazol y metodos para su suministro transdermico.

Country Status (11)

Country Link
US (2) US9138402B2 (es)
EP (1) EP2632463B1 (es)
JP (2) JP5966228B2 (es)
CN (2) CN103491961B (es)
AU (1) AU2011320758B2 (es)
BR (1) BR112013010190B1 (es)
CA (1) CA2816203C (es)
ES (1) ES2675913T3 (es)
MX (1) MX339196B (es)
RU (1) RU2589689C2 (es)
WO (1) WO2012058091A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
WO2014172344A1 (en) * 2013-04-16 2014-10-23 Alpha To Omega Pharmaceutical Consultants, Inc. Pharmaceutical compositions
US10356018B2 (en) * 2014-01-31 2019-07-16 Vivint, Inc. User management methods and systems
EP3233077B1 (en) 2014-12-19 2026-05-06 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016200830A1 (en) * 2015-06-08 2016-12-15 Corium International, Inc. Formulations for aripiprazole delivery transdermally
WO2017025912A1 (en) * 2015-08-13 2017-02-16 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
EP3448387A4 (en) * 2016-04-25 2019-12-11 Otsuka Pharmaceutical Co., Ltd. COMPOSITIONS OF PHARMACEUTICAL PRODUCT WITH RECOVERABLE EVENT MARKER
JP6625208B2 (ja) * 2016-05-12 2019-12-25 富士フイルム株式会社 経皮製剤
WO2018117125A1 (ja) * 2016-12-19 2018-06-28 富士フイルム株式会社 経皮製剤
WO2024226871A1 (en) * 2023-04-27 2024-10-31 Mccord Darlene E Compositions and methods of dissolving biofilm to promote wound healing

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101492A0 (en) 1992-04-03 1992-12-30 Shalom Levy Anti-skin rash preparation
EP0633024A1 (en) * 1993-07-09 1995-01-11 Ciba-Geigy Ag Topically administrable zinc phthalocyanine compositions
DE59509232D1 (de) * 1994-02-18 2001-06-13 Drossapharm Ag Basel Transdermales therapeutisches System
US5558071A (en) * 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
IL134830A0 (en) * 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
DE10030716A1 (de) * 2000-06-23 2002-01-03 Degussa Tieftemperaturschlagzähe Polymerlegierung
US20040170672A1 (en) * 2001-03-07 2004-09-02 Thorsten Selzer Transdermal therapeutic system for administration of partial dopamine-d2 agonists
DE10110953A1 (de) * 2001-03-07 2002-09-19 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von partiellen Dopamin-D2-Agonisten
CA2428237C (en) * 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
WO2005058835A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Methods of preparing aripiprazole crystalline forms
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
KR101329658B1 (ko) * 2006-09-25 2013-11-14 아처 다니엘 미드랜드 캄파니 초흡수성 표면처리된 카르복시알킬화 다당류 및 그 제조방법
CA2665101A1 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation
US20130084243A1 (en) * 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
CL2008003305A1 (es) * 2007-11-06 2009-06-05 M/S Panacea Biotec Ltd Composicion inyectable que comprende un agente activo seleccionado de un grupo definido; al menos un polimero bioerosionable, al menos un solvente no toxico y opcionalmente uno o mas excipientes; proceso de preparacion; uso para tratar enfermedades mentales o cancer.
WO2010036702A1 (en) * 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
GB0905365D0 (en) * 2009-03-27 2009-05-13 Norbrook Lab Ltd A topical parasiticide composition
EP2238976B1 (en) * 2009-04-03 2012-06-27 Hexal AG Oral films comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro- 1H-quinolin-2-one base or salts or hydrates thereof
WO2010146872A1 (ja) * 2009-06-19 2010-12-23 株式会社メドレックス アリピプラゾールと有機酸を有効成分とする外用剤組成物
US20110028412A1 (en) * 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
US9358261B2 (en) * 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
US9968740B2 (en) * 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9468206B2 (en) * 2014-12-31 2016-10-18 Valent U.S.A., Corporation Lactofen and dicamba diglycol amine liquid formulations

Also Published As

Publication number Publication date
JP2014503479A (ja) 2014-02-13
EP2632463B1 (en) 2018-04-04
US20130171237A1 (en) 2013-07-04
WO2012058091A2 (en) 2012-05-03
BR112013010190A2 (pt) 2016-09-13
RU2589689C2 (ru) 2016-07-10
CA2816203A1 (en) 2012-05-03
ES2675913T3 (es) 2018-07-13
JP5966228B2 (ja) 2016-08-10
CN107929239A (zh) 2018-04-20
CN107929239B (zh) 2021-06-01
CN103491961B (zh) 2018-01-02
US20130209552A1 (en) 2013-08-15
AU2011320758A1 (en) 2013-05-09
BR112013010190B1 (pt) 2019-12-31
WO2012058091A3 (en) 2013-10-17
CA2816203C (en) 2017-02-21
MX2013004693A (es) 2013-11-01
AU2011320758B2 (en) 2015-09-24
JP2016164204A (ja) 2016-09-08
EP2632463A2 (en) 2013-09-04
CN103491961A (zh) 2014-01-01
RU2013124401A (ru) 2014-12-10
EP2632463A4 (en) 2016-04-20
US9138402B2 (en) 2015-09-22

Similar Documents

Publication Publication Date Title
MX2013004693A (es) Composiciones de aripiprazol y metodos para su suministro transdermico.
GB201106750D0 (en) Novel compounds
PL2629754T3 (pl) Kompozycja farmaceutyczna w postaci ciekłej do podawania składników czynnych
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
PH12015501738A1 (en) Androgen receptor modulators and uses thereof
IL237318A0 (en) Chemical preparations and methods for increasing the delivery of therapeutic agents through the skin
IN2014CN00568A (es)
IL226327A (en) Nephrilicin inhibitors, pharmaceuticals containing them, and their use in the preparation of such preparations
AU2013235499A8 (en) Estrogen receptor modulators and uses thereof
PH12012502419A1 (en) Estrogen receptor modulators and uses thereof
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
IL235923B (en) Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical preparations thereof
IL236268A0 (en) Preparations for mucosal administration and their uses
IL234884A0 (en) Inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
PH12015501302A1 (en) Compositions comprising vortioxetine and donepezil
EP3054930A4 (en) Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
MX2014008693A (es) Administracion transdermica de hormonas.
EP2676555A4 (en) Use for high-molecular-weight polymer and composition including same
EP2908800B8 (en) Composition and delivery vehicle for active agents and methods therefor
HK1191848A (en) Aripiprazole compositions and methods for its transdermal delivery
EA201391703A1 (ru) Интраназальные биоадгезивные тестостероновые составы в виде гелей и их применение для лечения мужского гипогонадизма
HK1162316A (en) Improved pharmaceutical compositions and methods of delivery
HK1177101A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: AEQUUS PHARMACEUTICALS INC.